Delivery Order SPE2DB24D2216-SPE2DB25FGPHS
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,012.20 to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 ML syringes on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine product, reflecting the ongoing federal medical procurement needs for...
- The Defense Logistics Agency awarded a delivery order valued at $2,024.40 to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 ML syringes on August 19, 2025, with ultimate completion by August 20, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine commonly used across military and federal healthcare systems for disease prevention and immunization...
- The Defense Logistics Agency awarded a delivery order valued at $2,991.25 to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 mL syringes on August 7, 2025, with completion targeted for August 8, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance taking place at the contractor's Corporate Office location in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine commonly used in military and federal healthcare settings to...
- The Defense Logistics Agency awarded a delivery order valued at $2,024.40 to AmerisourceBergen Drug Corp on January 13, 2025, for the supply of HAVRIX 720 Unit/0.5 ML syringes. This firm fixed-price, non-set-aside contract will be completed by January 14, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine commonly used in military and federal healthcare settings, and this delivery order represents a routine...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,666.37 firm fixed price delivery order for 1,440 units of HAVRIX 1,440 Unit/mL syringe on April 18, 2025, with ultimate completion scheduled for April 21, 2025. This non-set-aside contract was competitively awarded to AmerisourceBergen's Corporate Office, with performance to occur at the company's Conshohocken, Pennsylvania headquarters. HAVRIX is a hepatitis A vaccine commonly utilized by the Department of Defense for...
- The Defense Logistics Agency awarded a delivery order valued at $11,651.70 to AmerisourceBergen Drug Corp for the supply of HAVRIX 720 Unit/0.5 ML syringes, with an ultimate completion date of September 15, 2025. This firm fixed-price contract, awarded on September 12, 2025, represents a non-competitive set-aside delivery and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine commonly utilized across military and federal...
- The Defense Logistics Agency awarded a delivery order valued at $1,012.20 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of HAVRIX 720 Unit/0.5 mL syringes. This non-competitive delivery order represents a firm fixed-price transaction with an ultimate completion date of August 20, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine commonly utilized by military and federal healthcare systems for disease...
- The Defense Logistics Agency awarded a $22,225.50 delivery order to AmerisourceBergen Drug Corp for 1,440 units of Havrix 1-mL syringes on June 6, 2025, with a completion date of June 9, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. Havrix is a hepatitis A vaccine commonly used in military and federal healthcare systems to maintain immunization...
- The Defense Logistics Agency awarded a delivery order valued at $2,501.85 to AmerisourceBergen Drug Corp for the supply of HAVRIX 1,440 UNIT/ML in syringe format. This competitively awarded, firm fixed-price contract was issued on August 27, 2025, with an ultimate completion date of August 28, 2025, and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine commonly utilized by military and federal healthcare systems for...
- The Defense Logistics Agency awarded a $11,463.02 delivery order to AmerisourceBergen Drug Corp for 1,440 units/mL of HAVRIX vaccine syringes on July 28, 2025, with completion targeted for July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPHSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,012.20 to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 mL syringes on July 28, 2025, with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine commonly used across military and federal healthcare systems to support troop readiness and disease prevention initiatives. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products, vaccines, and medical supplies to support Defense Health Agency operations and other government healthcare systems worldwide. The company's demonstrated capability to fulfill federal procurement requirements through open competition across multiple therapeutic domains makes it a key strategic partner for military medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 7/28/25 |